is an important stimulus for pulmonary vasoconstriction and vascular remodeling. Increased resting [Ca 2؉ ] cyt and enhanced Ca 2؉ influx have been implicated in PASMC from patients with idiopathic pulmonary arterial hypertension (IPAH).
due to receptor-operated Ca 2ϩ entry (ROCE) in PASMC. On activation of membrane receptors and subsequent increase in inositol 1,4,5-trisphosphate (IP 3 ) synthesis, SOC are opened by the depletion of Ca 2ϩ from the sarcoplasmic reticulum (SR), an important intracellular store in PASMC, to elicit store-operated Ca 2ϩ entry (SOCE) or capacitative Ca 2ϩ entry. SOCE is an important mechanism involved in maintaining a sustained elevation of [Ca 2ϩ ] cyt and refilling Ca 2ϩ into the SR.
We have previously demonstrated that the resting [Ca 2ϩ ] cyt is increased, whereas SOCE and ROCE are both enhanced in PASMC isolated from IPAH patients in comparison to PASMC isolated from normal subjects and patients without pulmonary hypertension. 6, 7 We have also shown that increased Ca 2ϩ influx during PASMC proliferation is due largely to the enhancement of SOCE; downregulation and blockade of SOC significantly inhibits PASMC proliferation. These results indicate that SOCE plays an important role in regulating cell proliferation in vascular smooth muscle cells. [2] [3] [4] 8 Furthermore, expression and activity of ROC and SOC are both upregulated in PASMC isolated from patients with IPAH and animals with hypoxia-induced pulmonary hypertension. 2,9 -11 Opening of ROC and SOC is caused initially by activation of various membrane receptors including G protein-coupled receptors (GPCR) and receptor tyrosine kinases. The extracellular Ca 2ϩ -sensing receptor (CaSR) is a member of GPCR subfamily C (also known as GPRC2A), [12] [13] [14] which was originally identified in the parathyroid glands and is activated by its ligands including Ca 2ϩ , Gd 3ϩ , Mg 2ϩ , polyamines, antibiotics, and amino acids. 12, 15 The CaSR is involved in multiple cellular processes of the parathyroid glands in response to changes in serum Ca 2ϩ concentrations such as proliferation, differentiation, and apoptosis. 12, 13, 15 In addition to parathyroid glands, the CaSR is also expressed in kidney, bone, smooth muscle, endothelium, gastrointestinal tract, and brain. 13,16 -19 The physiological and pathological significance of CaSR in the development and progression of pulmonary arterial hypertension, however, remains unknown.
In this study, we examined whether CaSR was involved in the enhanced Ca 2ϩ signaling and augmented proliferation in PASMC from patients with IPAH and whether inhibition of CaSR attenuates IPAH-PASMC proliferation and prevents the development of experimental pulmonary hypertension in animal models.
Methods

Preparation of Human and Animal PASMC
Human PASMC were isolated from normal control subjects and patients with IPAH and chronic thromboembolic pulmonary hypertension (CTEPH). 8, 20, 21 Approval to use the human lung tissues and cells was granted by the UIC Institutional Review Board. Human PASMC were cultured in Medium 199 supplemented with 10% fetal bovine serum at 37°C. The cells at passages 5 to 8 were used for the experiments. In some experiments, we also used freshly-dissociated PASMC from rats 22 and PASMC from mice. 23 [Ca 2؉ ] cyt Measurement [Ca 2ϩ ] cyt was measured in PASMC using fura-2 and a Nikon digital fluorescent imaging system. 24 Cells were loaded with 4 mol/L fura-2 acetoxymethyl ester (fura-2/AM) for 60 minutes at 25°C and [Ca 2ϩ ] cyt was measured using a ratiometric method at 32°C.
Western Blot
Solubilized protein isolated from PASMC, pulmonary arteries, and lung tissues was loaded on an 8% acrylamide gel, transferred to an Immobilon-P transfer membrane (Millipore, Bedford, MA), and immunoblotted with anti-CaSR monoclonal antibody (MA1-934, 1:200; Thermo Scientific, Rockford, IL). To isolate the fraction of cellular membrane, the cell lysate was centrifuged at 100 000g and then the pellet was resuspended to use for Western blot analysis. Signals were detected using a Super Signal West Pico Chemiluminescent Substrate (Thermo Scientific). The protein levels were normalized to ␤-tubulin (sc-9104, 1:200; Santa Cruz Biotechnology) and expressed in arbitrary units.
Transfection of cDNA and Small Interfering RNA
PASMC were transiently transfected with vector cDNA (2 g, pcDNA3.1[ϩ]), human CaSR cDNA (2 g), control small interfering RNA (siRNA) (50 nmol/L, sc-37007; Santa Cruz Biotechnology), or CaSR siRNA (50 nmol/L, s2440; Applied Biosystems, Austin, TX) using an Amaxa Basic Nucleofector kit for primary smooth muscle cells (Lonza). [Ca 2ϩ ] cyt measurements and Western blot using cDNA-and siRNA-transfected cells were preformed 48 to 72 hours after electroporation.
Proliferation Assay
Proliferation of PASMC was determined using an automated cell counter (TC10; Bio-Rad Laboratories, Hercules, CA). At 48 hours after subculture, PASMC were counted and replated (0 hours) into 8-well multidishes (Nunclon ⌬, 10.5 cm 2 of culture area per well; Thermo Scientific) with 1ϫ10 5 cells/well (0.95ϫ10 4 cells/cm 2 ).
Preparation of MCT-PH Rats and Hypoxia-Induced PH Mice
All experiments were approved by the Ethics/Animal Care Committee of University of Illinois at Chicago. For MCT-PH rat experiments, male Sprague-Dawley rats (190 -200 g) were treated with single subcutaneous (sc) injection of vehicle (dimethyl sulfoxide, DMSO) or 60 mg/kg MCT. For NPS 2143-treated group, rats were intraperitoneally injected (ip) with NPS 2143 at a dose of 4.5 mg/kg per day (from day 1-10). Fourteen days after injection, rats were anesthetized with ketamine/xylazine and then RVSP was measured using an MPVS Ultra system (Millar Instruments). For hypoxia- 
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Immunohistochemical and Hematoxylin and Eosin Staining
Immunohistochemistry and hematoxylin and eosin staining were performed using formalin-fixed and paraffin-embedded sections (3 m) from left lung lobes of rats. The tissue sections were treated with PBS containing 5% normal goat serum and either CaSR (1:100 dilution) or SM ␣-actin (1:100; EMD Millipore) antibody for 12 hours at 4°C. After washing repeatedly in PBS, the sections were covered with PBS containing Alexa Fluor 488-labeled (1:500 dilution) or Cy3-labeled (1:500) secondary antibody for 1 hour at room temperature and then rinsed with PBS. Then sections were mounted in VECTASHIELD hard-set mounting medium with DAPI (1.5 g/mL). To measure the external diameter of pulmonary arteries stained with hematoxylin and eosin, the microscopic images were analyzed using ImageScope software (Ver.11).
Drugs
Pharmacological reagents were obtained from Sigma-Aldrich except for KB-R7943, NPS 2143, and R568 (Tocris, Ellisville, MO). All hydrophobic compounds were dissolved in DMSO at the concentration of 10 or 100 mmol/L as a stock solution.
Statistical Analysis
Composite data are shown as the meanϮSE. The statistical significance between two groups was determined by Student t test. The statistical significance among groups was determined by Scheffe test after 1-way analysis of variance. Significant difference is expressed as PϽ0.05 or PϽ0.01.
Results
Extracellular Ca 2؉ Induces a Significant Increase in [Ca 2؉ ] cyt in IPAH-PASMC But Not in Normal PASMC
We first examined and compared the effects of extracellular Figure 1A through 1C (IPAH1 versus IPAH2), the kinetics of the extracellular Ca 2ϩ -induced increases in [Ca 2ϩ ] cyt were different in IPAH-PASMC. Approximately 48% of IPAH-PASMC tested (IPAH1) exhibited a rapid transient increase in [Ca 2ϩ ] cyt , whereas more than 50% of the cells (IPAH2) had a sustained plateau phase of [Ca 2ϩ ] cyt increase after the initial transient ( Figure 1A , middle panels, and Figure 1C ). In PASMC isolated from CTEPH patients superfused with Ca 2ϩ -free solution (for 10 minutes), restoration of extracellular Ca 2ϩ had no effect on [Ca 2ϩ ] cyt ( Figure 1A through 1C). The extracellular Ca 2ϩ -induced [Ca 2ϩ ] cyt increase in IPAH-PASMC was dependent on Ca 2ϩ concentration ( Figure  1D ); the EC 50 was approximately 1.22 mmol/L (nϭ57-183 cells), which resulted an increase of [Ca 2ϩ ] cyt by 1,250 nmol/L ( Figure 1D , right panel). In contrast, we were unable to detect a significant increase in [Ca 2ϩ ] cyt in normal PASMC with restoration of 10 mmol/L extracellular Ca 2ϩ ( Figure 1D ).
Protein Expression of CaSR in IPAH-PASMC Is Greater Than in Normal PASMC
To investigate the potential mechanism of extracellular Ca 2ϩmediated increase in [Ca 2ϩ ] cyt , we compared the protein expression level of CaSR in normal and IPAH PASMC. As shown in Figure 2 , the protein expression of CaSR in IPAH-PASMC (Figure 2A and 2B) and lung tissues from IPAH patients ( Figure 2C and Online Figure I ) was significantly higher than in normal PASMC and lung tissues in both total protein lysates and in the membrane bound fraction (nϭ5, PϽ0.01). These data indicate that upregulation of CaSR may be involved in the enhanced Ca 2ϩ -induced [Ca 2ϩ ] cyt increase in IPAH-PASMC.
The Extracellular Ca 2؉ -Induced [Ca 2؉ ] cyt Rise in IPAH-PASMC Is Not Due Simply to Ca 2؉ Leakage
To rule out the possibility that the extracellular Ca 2ϩ -induced [Ca 2ϩ ] cyt increase in IPAH-PASMC was caused by membrane leakage to Ca 2ϩ , we first compared the resting [Ca 2ϩ ] cyt in normal and IPAH-PASMC. In cells superfused with 2.2 mmol/L Ca 2ϩ -containing solution, the resting [Ca 2ϩ ] cyt in IPAH-PASMC (nϭ370 cells) was significantly higher than in normal PASMC (nϭ96 cells). Removal of extracellular Ca 2ϩ negligibly affected the resting [Ca 2ϩ ] cyt in normal PASMC but significantly decreased the resting [Ca 2ϩ ] cyt in IPAH-PASMC (Online Figure IIA) . To examine whether IPAH-PASMC had leaky membranes, we incubated normal and IPAH PASMC with trypan blue (TB). No blue (TB-stained) cells were detected in normal and IPAH PASMC incubated in TB-containing solution, whereas after treatment of the cells with 10 mol/L ionomycin (for 10 minutes), a Ca 2ϩ ionophore, all normal and IPAH PASMC were TB-stained; there was no difference between normal and IPAH PASMC (Online Figure IIB ). Furthermore, we were unable to detect any fluorescent signals in normal and IPAH PASMC incubated with the membrane-impermeable fura-2 (Online Figure IIC ). All these experiments indicate that the extracellular Ca 2ϩ -induced [Ca 2ϩ ] cyt increase in IPAH-PASMC was not due to Ca 2ϩ leakage through the plasma membrane.
Effects of Specific CaSR Modulators on the Extracellular Ca 2؉ -Induced [Ca 2؉ ] cyt Increase in Normal and IPAH-PASMC
To further confirm that the upregulated CaSR in IPAH-PASMC is involved in the enhanced extracellular Ca 2ϩinduced [Ca 2ϩ ] cyt rise, we examined whether the polyamine spermine and the calcimimetic R568 induced the same effect on [Ca 2ϩ ] cyt as did restoration of extracellular Ca 2ϩ , and whether the calcilytic NPS 2143 inhibited the extracellular Ca 2ϩ -induced [Ca 2ϩ ] cyt increase. As shown in Figure 3A Figure 3B ), whereas the negative allosteric modulator of CaSR, NPS 2143 (10 mol/L), significantly inhibited extracellular Ca 2ϩ -mediated increase in [Ca 2ϩ ] cyt ( Figure 3C ). Collectively, these results demonstrate that the upregulated CaSR ( Figure 2 ) is involved in the enhancement of the extracellular Ca 2ϩ -induced [Ca 2ϩ ] cyt increase in PASMC from IPAH patients.
Extracellular Ca 2؉ -Induced [Ca 2؉ ] cyt Increase in IPAH-PASMC Is Dependent of Phospholipase C and the Inositol-2,4,5-Trisphosphate Receptor
To examine the potential signaling pathway involved in the CaSR-mediated increase in [Ca 2ϩ ] cyt in IPAH-PASMC, we performed pharmacological experiments on the extracellular Ca 2ϩ -mediated increase in [Ca 2ϩ ] cyt . As shown in Figure 4 , short-time pretreatment of IPAH-PASMC with the inhibitor of phospholipase C (PLC), U73122 (1 mol/L), or the specific blocker of Inositol-2,4,5-Trisphosphate receptor (IP 3 R), xestospongin C (3 mol/L), significantly inhibited the extracellular Ca 2ϩ -induced increase in [Ca 2ϩ ] cyt (Online Figure IIIA and C). The inactive form of U73122, U73343 (1 mol/L), however, had no effect on the extracellular Figure IIIB) . Pretreatment of IPAH-PASMC with the blocker of VDCC, diltiazem (10 mol/L) or the inhibitor of Na ϩ /Ca 2ϩ exchanger KB-R7943 (10 mol/L), however, had no effect on the extracellular Ca 2ϩ -induced increase in [Ca 2ϩ ] cyt (Online Figure IIID and E). These results indicate that activation of PLC and IP 3 R is involved in the CaSR-mediated [Ca 2ϩ ] cyt increase in IPAH-PASMC, whereas VDCC and the reverse mode of Na ϩ /Ca 2ϩ exchanger are not involved in the Ca2Rmediated Ca 2ϩ influx or inward transportation.
Ca 2ϩ -induced increase in [Ca 2ϩ ] cyt (Online
Downregulation of CaSR in IPAH-PASMC Inhibits Extracellular Ca 2؉ -Induced [Ca 2؉ ] cyt Increase and Attenuates Cell Proliferation
To obtain direct evidence for the involvement of CaSR in extracellular Ca 2ϩ -induced [Ca 2ϩ ] cyt increase and cell proliferation, we used siRNA to knockdown CaSR expression and examined whether CaSR was necessary for the extracellular Ca 2ϩ -induced [Ca 2ϩ ] cyt increase in IPAH-PASMC. Treatment of IPAH-PASMC with 50 nmol/L siRNA significantly decreased protein level of CaSR ( Figure 4A ) and markedly inhibited the extracellular Ca 2ϩ -induced increase in [Ca 2ϩ ] cyt ( Figure 4B ). In comparison to normal PASMC, the proliferate rate of IPAH-PASMC, determined by a change in cell number, was much faster ( Figure 4C ), whereas downregulation of CaSR in IPAH-PASMC by transiently transfecting 50 nmol/L siRNA for CaSR significantly attenuated cell proliferation ( Figure 4D ). These experiments provide compelling evidence that CaSR is necessary for the augmented extracellular Ca 2ϩ -induced [Ca 2ϩ ] cyt increase and enhanced cell proliferation in IPAH-PASMC.
Overexpression of CaSR in Normal PASMC Augments the Extracellular Ca 2؉ -Induced [Ca 2؉ ] cyt Increase and Enhances Cell Proliferation
Extracellular application of either 2.2 mmol/L Ca 2ϩ or 3 mmol/L spermine failed to induce a significant increase in [Ca 2ϩ ] cyt in normal PASMC because of a low protein expression level of CaSR (Figures 2 and 3 ). We examined whether CaSR was sufficient to mediate extracellular Ca 2ϩinduced [Ca 2ϩ ] cyt increase in both human and rat PASMC by transiently transfecting the human CaSR into normal PASMC. As shown in Figure 5 , overexpression of CaSR (with 2 g of the human CaSR cDNA) in normal (human and rat) PASMC significantly augmented the extracellular Ca 2ϩmediated increase in [Ca 2ϩ ] cyt ( Figure 5A and 5B) and enhanced cell proliferation ( Figure 5C ) in comparison to normal PASMC transiently transfected with an empty vector. Taken together with the data showed earlier (Figure 4 ), these results indicate that (1) CaSR is sufficient to mediate extracellular Ca 2ϩ -induced [Ca 2ϩ ] cyt increase and cell proliferation in normal PASMC, and (2) CaSR is necessary for the augmented extracellular Ca 2ϩ -induced [Ca 2ϩ ] cyt increase and enhanced cell proliferation in IPAH-PASMC.
CaSR Is Functionally Upregulated in PASMC from Animal Models of Experimental Pulmonary Hypertension, and Blockade of CaSR Prevents the Development of PH
The presented in vitro experimental data show that the upregulated CaSR and augmented extracellular Ca 2ϩmediated [Ca 2ϩ ] cyt increase in PASMC are involved in the enhanced PASMC proliferation in patients with IPAH. To investigate whether CaSR can be a target for treatment of pulmonary arterial hypertension, we used the rat model of monocrotaline (MCT)-induced pulmonary hypertension (MCT-PH) and the mouse model of HPH to test the potential therapeutic effect of the calcilytic NPS 2143. We first examined and compared the mRNA and protein expression level of CaSR in PASMC from control and MCT-treated rats. As shown in Figure 6A and 6B, the mRNA level of CaSR in PASMC isolated from rats (rPASMC) with MCT-PH was much greater than in PASMC isolated from normotensive control rats injected with vehicle. The immunohistochemistry and immunoblotting experimental data indicate that the protein expression level of CaSR in the small pulmonary artery ( Figure 6C ) and PASMC ( Figure 6D ) of MCT-rats was significantly higher than in the small pulmonary artery and PASMC of control rats. Furthermore, the basal or resting [Ca 2ϩ ] cyt and the extracellular Ca 2ϩ -induced increase in [Ca 2ϩ ] cyt were both enhanced in freshly-dissociated PASMC from MCT-PH rats compared with freshly-dissociated PASMC from normotensive control rats ( Figure 6E ). Treatment with NPS 2143 not only decreased the basal [Ca 2ϩ ] cyt , but also inhibited the extracellular Ca 2ϩ -induced increase in [Ca 2ϩ ] cyt in PASMC isolated from MCT-PH rats ( Figure 6E ). These results imply that upregulation of CaSR and subsequent enhancement of extracellular Ca 2ϩ -induced [Ca 2ϩ ] cyt increase in PASMC contribute to the development of pulmonary hypertension in rats injected with MCT.
To test the in vivo therapeutic effect of the CaSR antagonist, we examined and compared the right ventricular systolic pressure (RVSP), the Fulton index [ie, the ratio of right ventricle/left ventricleϩseptum, RV/(LVϩS)], and muscularization of distal pulmonary arteries in normotensive control (Norm) rats and MCT-injected rats with and without treatment with NPS 2143, a CaSR antagonist. Injection of MCT (60 mg/kg) in rats significantly increased RVSP and caused right ventricular (RV) hypertrophy compared with the normotensive control (Norm) rats injected with vehicle (DMSO) ( Figure 7A through 7C). Intraperitoneal injection of NPS 2143 (4.5 mg/kg per day) had little effect on RVSP and RV/(LVϩS) ratio in Norm rats but significantly attenuated the increase in RVSP and the Fulton index in MCT-PH rats ( Figure 7A through 7C ). There were no significant changes in heart rate in Norm rats with (412Ϯ17 bpm, nϭ6) or without (411Ϯ21 bpm, nϭ6) NPS treatment and MCT-injected rats with (414Ϯ23 bpm, nϭ6) or without (413Ϯ21 bpm, nϭ6) NPS treatment. The MCT-induced increases in RVSP and RV hypertrophy were associated with significant pulmonary vascular remodeling; the vascular medial wall thickness of small pulmonary arteries with the outer diameter less than 100 m was significantly greater in MCT-injected rats than in Norm rats ( Figure 7D and 7E). Treatment with the CaSR antagonist (NPS 2143) significantly inhibited the muscularization of small pulmonary arteries ( Figure 7D and 7E). The in vivo animal experiments are consistent with the in vitro experiments using normal and IPAH PASMC.
To further validate the pathogenic role of upregulated CaSR in the development of pulmonary hypertension and the therapeutic effect of CaSR antagonists on experimental pulmonary hypertension, we repeated the experiments mentioned above in the HPH mouse model. As shown in Figure 8 , the mRNA and protein expression of CaSR was significantly higher in pulmonary arteries and lung tissues in HPH mice than in normoxic control mice ( Figure 8A and 8B), whereas the extracellular Ca 2ϩ -induced increase in [Ca 2ϩ ] cyt in freshly isolated PASMC from HPH mice was significantly enhanced in comparison to cells from normoxic mice ( Figure 8C ). These data indicate that CaSR is functionally upregulated in PASMC from HPH mice.
Intraperitoneal injection of NPS 2143 (1 mg/kg per day from day 1-10) had little effect on RVSP and RV/(LVϩS) ratio in normoxic control mice (Nor) but significantly inhibited the increase in RVSP and RV/(LVϩS) ratio in hypoxic mice (Hyp) ( Figure 8D through 8F ). Furthermore, inhibition of CaSR also significantly inhibited the hypoxia-mediated pulmonary arterial wall thickening ( Figure 8G ) and reversed the hypoxia-induced decrease in branch and junction numbers (and total length) of small pulmonary arterial trees ( Figure 8H and 8I ). There were no significant changes in heart rate in normoxic mice with (411Ϯ17 bpm, nϭ6) or without (410Ϯ20 bpm, nϭ6) NPS treatment and hypoxic mice with (412Ϯ18 bpm, nϭ6) or without (413Ϯ18 bpm, nϭ6) NPS treatment.
These data imply that intraperitoneal injection of the CaSR antagonist is an efficient therapeutic approach to inhibit the development and progression of pulmonary vascular remodeling and right ventricular hypertrophy in animal models with experimental pulmonary hypertension induced by injection of monocrotaline and exposure to hypoxia. The observations from this study strongly indicate that increased expression and function of CaSR may play a pathogenic role in the development of pulmonary vascular remodeling and antagonists of CaSR, or calcilytics, may have great therapeutic potential for patients with pulmonary arterial hypertension.
Discussion
In this study, we found that (1) [Ca 2ϩ ] cyt plays an important role in the regulation of contraction, proliferation, and migration of PASMC. An increase in [Ca 2ϩ ] cyt in PASMC is a major trigger for pulmonary vasoconstriction and an important stimulus for PASMC proliferation and pulmonary vascular remodeling under pathological conditions. Elevation of [Ca 2ϩ ] cyt in PASMC results from Ca 2ϩ release from intracellular stores and Ca 2ϩ influx through plasmalemmal Ca 2ϩ channels. 1, 5 We 
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previously showed that the resting [Ca 2ϩ ] cyt was increased, whereas ROCE and SOCE were enhanced in PASMC from IPAH patients compared with PASMC from normal subjects and patients without pulmonary hypertension. 6, 7 CaSR is a GPCR (belongs to the Family C GPCR) with 1085 amino acids, which is present constitutively in a homodimeric configuration formed by covalent and noncovalent linkages [25] [26] [27] and is able to form heterodimers with the metabotropic glutamate receptors (mGLuR1 and mGluR5). 27 One of the hallmarks of CaSR is the cysteine-rich large N-terminal extracellular domain (ECD, approximately 600 amino acids). The region between alanine 116 and proline 136 in the ECD is important for maintaining CaSR in an inactive conformation 28 and is associated with the activating mutations or single nucleotide polymorphism (SNPs) identified in the human CaSR gene. The ligands or activators of CaSR include polyvalent cations (eg, Ca 2ϩ , Mg 2ϩ , Gd 3ϩ ), polypeptides (eg, amyloid-␤ peptide), polyamines (eg, spermine, spermidine, putrescine), aminoglycoside antibiotics (eg, neomycin, kanamycin), and amino acids (eg, phenylalanine, tyrosine, tryptophan, glutamate). In addition, there are synthetic CaSR activators, or calcimimetics (eg, NPS-R-568, NPS-R-467), and CaSR antagonists, or calcilytics (eg, NPS 2143), that affect CaSR function. 12-14,29 -31 The cysteinerich domain in the ECD also sensitizes the receptor to redox changes and hypoxia/hyperoxia. In Sprague-Dawley rats, treatment with the CaSR activator or the calcimimetic R-568 atten-uates aortic wall thickening induced by uremia. 32 Our data from this study, however, indicate that the extracellular Ca 2ϩmediated [Ca 2ϩ ] cyt increase in IPAH-PASMC was potentiated by NPS-R-568, an allosteric agonist of CaSR, and inhibited by NPS 2143, an allosteric antagonist of CaSR. Extracellular application of spermine significantly increased [Ca 2ϩ ] cyt in IPAH-PASMC superfused in Ca 2ϩ -containing solution. These data imply that multiple ligands can activate the upregulated CaSR in IPAH-PASMC leading to cell proliferation, contraction and migration via Ca 2ϩ signaling and other signal transduction cascades.
Extracellular Ca 2ϩ binding to CaSR is a highly cooperative process. The EC 50 for extracellular Ca 2ϩ -induced [Ca 2ϩ ] cyt increase in IPAH-PASMC is approximately 1.2 mmol/L ( Figure  1D ), whereas the EC 50 has been reported to be 1.7 mmol/L in parathyroid cells, 33 1.5 mmol/L in cardiomyocytes, 34 and 5.6 mmol/L in bronchial epithelial cells. 35 However, in reconstituted systems with CaSR clones isolated from parathyroid glands, the EC 50 for CaSR activation (or the Ca 2ϩ sensitivity of CaSR) is 3.0 to 3.5 mmol/L. 12,13,15,36 -38 The lower EC 50 for Ca 2ϩ -induced [Ca 2ϩ ] cyt rise in IPAH-PASMC and native vascular smooth muscle cells (compared with the EC 50 for the recombinant CaSR) is presumably due to the high degree of cooperativity in the interaction between the upregulated CaSR (eg, in IPAH-PASMC) and ligands. CaSR is always exposed to various coagonists physiologically (eg, Mg 2ϩ , polyamines, and amino acids) and other activators pathologically (eg, antibiotics, heavy metals, and amyloid-␤ peptide). Therefore, the sensitivity of CaSR to extracellular Ca 2ϩ is expected to be higher in pathologically conditions than in physiological conditions.
As mentioned earlier, the CaSR senses extracellular Ca 2ϩ concentration and transduces it to intracellular space though multiple signal pathways. [12] [13] [14] 18 CaSR interacts directly with G proteins (G q␣ and G 11␣ ). Activation of CaSR by extracellular Ca 2ϩ (or calcimimetics) induces increases in [Ca 2ϩ ] cyt through PLC-mediated hydrolysis of phosphatidylinositol-4,5bisphosphate (PIP 2 ) to inositol-1,4,5-trisphosphate (IP 3 ) and diacylglycerol (DAG). IP 3 binds to the IP 3 receptor (IP 3 R) on the SR membrane and induces Ca 2ϩ release from the SR to the cytosol. Depletion (or reduction) of Ca 2ϩ from the intracellular stores (ie, SR) via activated IP 3 R (or opened Ca 2ϩ release channels) then causes SOCE through SOC in the plasma membrane. Furthermore, DAG causes ROCE by activating ROC in the plasma membrane. The IP 3 -mediated Ca 2ϩ mobilization, the store depletion-mediated SOCE and the DAGmediated ROCE all contribute to the increase in [Ca 2ϩ ] cyt on activation of CaSR in the plasma membrane by extracellular Ca 2ϩ and CaSR activators. In IPAH-PASMC, the extracellular Ca 2ϩ -mediated [Ca 2ϩ ] cyt increases were significantly attenuated by the PLC inhibitor (U73122) and the IP 3 R blocker (xestospongin C) but not affected by the voltage-dependent Ca 2ϩ channel blocker (diltiazem) and the Na ϩ /Ca 2ϩ exchanger inhibitor (KB-R7943) (Online Figure III) . These data further confirm the important role of the PLC-IP 3 signaling cascade in CaSRmediated increase [Ca 2ϩ ] cyt and its proliferative effect on PASMC isolated from patients with IPAH. Most membrane receptors, including many GPCRs, become desensitized with prolonged exposure to agonists. However, CaSR desensitizes very slowly, 39 indicating that CaSR signals for long periods of time through the regulation of intracellular signaling cascades and other signal transduction pathways.
In addition to increasing [Ca 2ϩ ] cyt , extracellular Ca 2ϩmediated activation of CaSR has been linked to several signal transduction cascades. CaSR activates the mitogen-activated protein kinase (MAPK) cascade, for example, extracellular signal-regulated kinase 1/2 (ERK1/2), p38, and c-jun N-terminal kinase (JNK), potentially through the interaction with filamin A scaffolding protein and caveolin-1 in cholesterol-rich invaginations in the plasma membrane known as caveolae. 16,17,40 -44 In IPAH-PASMC, the number of caveoli and the protein expression level of caveolin-1/-2 are both increased, which are associated with increased SOCE. 45 Downregulation of caveolin-1 with siRNA and treatment with methyl-␤-cyclodextrin (M␤CD) significantly diminish the number of caveoli on the surface membrane of IPAH-PASMC, significantly attenuate SOCE, and markedly inhibit cell proliferation. 6, 45 It is unknown, however, whether upregulated CaSR in IPAH-PASMC is exclusively or predominantly localized in caveoli and functionally interacts with upregulated TRPC3/C6 channels. 7, 8 CaSR is widely distributed in the parathyroid glands, 15 kidney, 46 bone, 47 gastrointestinal tract, 48 skin, 49 brain, 50 immune cells, 51 and heart. 34 In addition, CaSR is expressed in vascular smooth muscle cells from rat subcutaneous artery, 52 aorta, 53 pulmonary artery, 16, 17 gerbil spiral modiolar artery, 54 human renal artery, 55 aorta, 55, 56 and internal mammary artery, 57 as well as in endothelial cells from rat mesenteric artery, porcine coronary artery, 58 and human aorta. 19 Activation of CaSR in vascular smooth muscle cells increases [Ca 2ϩ ] cyt and induces vasoconstriction 17, 54, 56 ; therefore, CaSR is involved in regulating myogenic tone, peripheral vascular resistance, 52 and arterial blood pressure. 59, 60 Recent observations demonstrate that the CaSR in vascular smooth muscle cells contributes to regu- lating cell proliferation and apoptosis through the MEK1/ ERK1/2 and PLC signaling pathways 17, 53, 55 and expression of CaSR is involved in the regulation of mouse lung development. 61 Our study indicated that in normal human PASMC, CaSR protein was expressed at a low level and extracellular application of Ca 2ϩ (from 0.5-10 mmol/L) failed to cause a significant increase in [Ca 2ϩ ] cyt ( Figure 1D ), whereas extracellular application of spermine caused a small increase in [Ca 2ϩ ] cyt ( Figure 3A) . These observations imply that CaSR is expressed at very low level in normal human PASMC and is not a major contributor to the regulation of pulmonary vascular tone under physiological conditions.
In patients with IPAH and animals with experimental pulmonary hypertension, CaSR is functionally upregulated in PASMC and thus becomes an important GPCR involved in the initiation and progression of pulmonary vascular remodeling and pulmonary hypertension. Knockdown of CaSR with siRNA in PASMC from IPAH patients not only diminished extracellular Ca 2ϩ -induced increase in [Ca 2ϩ ] cyt but also inhibited cell proliferation (Figure 4 ). Overexpression of CaSR in PASMC from normal subjects conferred an extracellular Ca 2ϩ -induced increase in [Ca 2ϩ ] cyt and enhanced cell proliferation ( Figure 5 ).
These experimental data provide compelling evidence that CaSR is necessary and sufficient for the augmented Ca 2ϩ signaling and excessive PASMC proliferation in IPAH patients. In this scenario, Ca 2ϩ is an extracellular ligand and an intracellular signaling element involved in the development and progression of sustained pulmonary vasoconstriction and vascular remodeling in patients with IPAH. The pathogenic role of upregulated CaSR in pulmonary hypertension is further confirmed by the therapeutic effect of CaSR antagonists on experimental pulmonary hypertension in rats injected with MCT and in mice exposed to chronic hypoxia.
The gain-of-function (or activating) mutations or SNP in the human CaSR gene causes autosomal dominant hypocalcemia 62 and Bartter syndrome type V. 12, 63 CaSR antagonists (calcilytics), that is, negative allosteric modulators that indirectly stimulate parathyroid hormone secretion through a decrease in CaSR activity, are potential drug candidates for the treatment of osteoporosis and other bone metabolism diseases. 64, 65 Using 2 well-established animal models of pulmonary hypertension (MCT-injected rats and chronic hypoxic mice), we found that increased RVSP and pulmonary vascular medial hypertrophy, as well as right ventricular 6 through 8) . Intraperitoneal injection of the CaSR antagonist NPS 2143 (4.5 mg/kg once a day) had little effect on the pulmonary hemodynamics and the Fulton index in control rats or normoxic mice, but significantly decreased RVSP, RV/(LVϩS) ratio and small pulmonary vascular wall thickening in rats with MCT-PH ( Figure 7) and mice with HPH ( Figure 8) . These results strongly suggest that CaSR is involved in the development of experimental pulmonary hypertension and a potential target for developing therapeutic approach for pulmonary arterial hypertension.
In conclusion, upregulated expression of CaSR in PASMC and augmented function of CaSR through intracellular Ca 2ϩ signaling (and other signal transduction cascades) are new pathogenic mechanisms involved in the initiation and progression of pulmonary vascular remodeling in patients with pulmonary arterial hypertension. Pharmacological blockade of CaSR in the pulmonary vasculature by synthetic calcilytics and downregulation of CaSR by siRNA (and/or specific microRNA) may be a novel therapeutic approach for IPAH patients who do not respond to the conventional drug therapy.
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Online Supplementary METHODS
Preparation of human and animal PASMC. Human PASMC were isolated from explanted lung tissues of normal control subjects (2 unsuitable organ donors and 2 COPD patients without pulmonary hypertension) and patients with IPAH (3 patients diagnosed on the basis of NIH IPAH Registry with an averaged mean PAP of 56±5 mmHg). 1, 2 In addition, PASMC were isolated and prepared from endarterectomized pulmonary arterial tissues of patients with chronic thromboembolic pulmonary hypertension (CTEPH, 4 patients with an averaged mean PAP of 39±5 mmHg) 3 . Approval to use the human lung tissues and cells was granted by the UIC Institutional Review Board. Human PASMC were cultured in Medium 199 supplemented with 10% fetal bovine serum (Invitrogen, Grand Island, NY), 100 U/ml penicillin plus 100 g/ml streptomycin, 50 g/ml D-valine (Sigma-Aldrich, St. Louis, MO), and 20 g/ml endothelial cell growth supplement (BD Biosciences, Franklin Lakes, NJ) at 37ºC. The cells at passages 5 to 8 were used for the experiments. In some experiments, we also used freshly-dissociated PASMC from rats (by a modified protocol based on the methods published previously). 4 In the modified protocol, cell suspensions were plated onto cover slips for a short time (2-3 hrs) before experiments. We also used PASMC from mice by a modified method previously published by Marshall et al. 5 .
[Ca 2+ ] cyt measurement. The [Ca 2+ ] cyt measurement was performed as described previously 6 . In brief, cultured PASMC on cover slips were placed in a recording chamber on the stage of an invert fluorescent microscope (Eclipse Ti-E; Nikon, Tokyo, Japan) equipped with an objective lens (S Plan Fluor 200.45 ELWD; Nikon), an EM-CCD camera (Evolve; Photometrics, Tucson, AZ), and NIS Elements 3.2 software (Nikon). The cells were loaded with 4 M fura-2 acetoxymethyl ester (fura-2/AM; Invitrogen/Molecular Probes, Eugene, OR) for 60 min at room temperature (25C). The HEPES-buffered external solution contained an ionic composition of 137 mM NaCl, 5.9 mM KCl, 2.2 mM CaCl 2 , 1.2 mM MgCl 2 , 14 mM glucose, and 10 mM HEPES (pH 7.4 with NaOH). In the Ca 2+ -free solution, 2.2 mM CaCl 2 was replaced by equimolar MgCl 2 and 1 mM EGTA was added to chelate the residual Ca 2+ . The fura-2-loaded cells in the recording chamber were continuously perfused with HEPES-buffered solution at 32C for 30 min to wash out extracellular fura-2/AM and allow sufficient time for the intracellular esterase to cleave acetoxymethyl ester from fura-2 so it can stay in the cytosol. The cells were then excited with 340-nm and 380-nm wavelength (D340×v2 and D380×v2 filters, respectively; Chroma Technology, Bellows Falls, VT) by a xenon arc lamp (Lambda LS; Sutter Instrument, Novato, CA) and an optical filter changer (Lambda 10-B; Sutter Instrument). Fura-2 fluorescence (or emission of fura-2) from a region of interest (5×5 μm) of PASMC, as well as background fluorescence, was collected through a dichroic mirror (400DCLP; Chroma Technology) and a wide band emission filter (D510/80m; Chroma Technology). The fluorescence signals emitted from the region of interest in cells were monitored and recorded continuously on a Nikon digital imaging fluorescence microscopy system and recorded in a PC. The ratio (R) of 340-nm and 380-nm fluorescence intensities (F 340 /F 380 ), recorded every 2 seconds, was then used to calculate [Ca 2+ ] cyt using the following equation: [Ca 2+ ] cyt = Kd × (S f2 /S b2 ) × (R-R min )/(R max -R), where Sf2 and Sb2 are the emission fluorescence values at 380-nm excitation in the presence of EGTA and triton X-100, respectively; K d (225 nM) is the dissociation constant of the Ca 2+ -fura-2 complex; and R max and R min were calculated according to the standard protocol. 7, 8 Pharmacological Experiments in Rats with MCT-PH. Adult male Sprague-Dawley rats (190-200 g in body weight; Charles River Laboratories, Wilmington, MA) were randomly divided into two groups: 1) normal control group which was injected subcutaneously of vehicle (DMSO); 2) MCT-PH group which was given a subcutaneous injection of MCT (60 mg/kg, Sigma-Aldrich) to induce pulmonary hypertension. The normal control group was further divided into two subgroups (n=6 for each): one subgroup received the intraperitoneal injection of NPS2143 (Tocris, solubilized into DMSO) at a dose of 4.5 mg/kg per day (from day 1 to day 10) and the other subgroup was injected intraperitoneally with the vehicle (DMSO) (from day 1 to day 10). The MCT-PH group was also further divided into two subgroups (n=6 for each): one subgroup received the intraperitoneal injection of NPS2143 at a dose of 4.5 mg/kg per day (from day 1 to day 10) and the other subgroup was injected intraperitoneally with the vehicle (DMSO) (from day 1 to day 10). Two weeks (14 days) later, the rats were anesthetized with ketamine (100 mg/kg, i.p.) and xylazine (26 mg/kg, i.p.) and then right ventricular pressure (RVP) was measured by a pressure-transducer catheter (Millar Instruments: SPF869 and SPF1030) inserted into the right ventricle through the right jugular vein. The hemodynamic data were recorded using an MPVS Ultra ® data acquisition system and analyzed with an AD Instruments Lab Chart Pro7.0 software. The protocol used for the rat experiments was approved by the Animal Care Committee of the University of Illinois at Chicago.
Pharmacological Experiments in Mice with HPH. Male C57BL/6N mice (18-22 g in body weight and 6 weeks of age, Charles River Laboratories, Wilmington, MA) were randomly divided into two groups: normoxic control group and hypoxic group which were placed into a normobaric hypoxic chamber (10% O 2 ) for 4 weeks to establish pulmonary hypertension. The normoxic group was further divided into two subgroups (n=6 for each): one subgroup received the intraperitoneal injection of NPS2143 at a dose of 1 mg/kg per day (from day 1 to day 22) and the other subgroup was injected intraperitoneally with the vehicle (DMSO) (from day 1 to day 22). The hypoxic group was also further divided into two subgroups (n=6 for each): one subgroup received the intraperitoneal injection of NPS2143 at a dose of 1 mg/kg per day (from day 1 to day 22) and the other subgroup was injected intraperitoneally with the vehicle (DMSO) (from day 1 to day 22). Four weeks (28 days) later, the mice were anesthetized with ketamine/xylazine (i.p.) and then right ventricular pressure (RVP) was measured by the right heart catheterization similar to that protocol for rats. The hemodynamic data were recorded using the MPVS Ultra ® data acquisition system and analyzed with the AD Instruments Lab Chart Pro7.0 software. The protocol used for the mouse experiments was approved by the Animal Care Committee of the University of Illinois at Chicago.
Assessment of Pulmonary Artery Thickness.
The left lung lobes (from rats or mice) were fixed in a 3% paraformaldehyde solution and the lobes were dissected in the middle for paraffin embedding. Sectioning at 3 µm was performed for all paraffin-embedded tissue blocks. H&E staining was performed according to common histopathological procedures. Histological analysis was performed in a blinded way: the person who dissected the lobes coded the tissue blocks with numbers and gave to another person to analyze the pulmonary vascular wall thickness. Microscopic images were analyzed using a computerized morphometric system (Aperio Imagescope v11.1.2.752 software) to assess the pulmonary arterial wall thickness. Pulmonary arteries were categorized according to their external diameter: category 1 are the arteries with an external diameter between 25 and 50 µm; category II are the arteries with an external diameter between 51 and 100 µm; and category III are the arteries with an external diameter greater than 100 µm. Thickness of an artery was determined by the average values obtained in multiple areas of the artery.
Angiography in Rats and Mice. Rats and mice were anesthetized to dissect out the whole lungs. A PE10 (BD) tube was inserted into the main pulmonary artery and superfused with warm PBS solution (36-38°C) via a syringe pump (Syringepump.com NE-300) at a rate of 0.25 ml/min for 4 min. Then MICROFIL® Silicone Rubber Injection Compounds (Flow-Tech, Inc., Carver, MA), a liquid silicon polymer, was infused into the main pulmonary artery at 0.25 ml/min for 4 min using the syringe infusion pump. The MICROFIL-infused lung tissues were stored at 4°C for 12 hrs before the lungs were sequentially bathed in ethanol at gradually increased concentrations. The tissues were then placed in methyl-salicylate and photographed with a digital camera (MD600E, Amscope, USA) through a dissecting microscope (WILD M651, Leica, Switzerland). The ImageJ software was used to evaluate the number of arterial branches, the number of arterial junctions and the total length of arterial segments in a given area (usually a square mm area, i.e., 1 mm 2 ). We selected the areas (in 1 mm 2 unit) of the lung vascular images with Photoshop CS software, and made binary images using ImageJ software. The pictures were then skeletonized for analyzing the vessel branches, junctions and total length. These data were normalized by the area selected in each lung.
Immunofluorescence Staining of Human and Rat Lung Sections. Immunohistochemistry for
CaSR and SM-α-actin was performed on formalin-fixed, paraffin-embedded (human, rat and mouse) lung tissue sections. Briefly, sections were first deparaffinized in xylene, rehydrated in graded ethanol solutions, and rinsed in deionized water. Then, sections were incubated (for 30 min) in a Tris-EDTA Buffer (10 mM Tris Base,1 mM EDTA solution, with 0.05% Tween20; pH 9.0) for heat-induced epitope retrieval. After washing in PBS, the sections were blocked by incubating with 5% bovine serum albumin (Sigma) for 1 hr. The slides were rinsed in PBS and incubated first with a CaSR polyclonal antibody (rabbit anti-mouse IgG, Abcam) at a dilution of 1:50 for 1 day at 4°C. Then the slides were incubated with a monkey anti-rabbit IgG antibody conjugated with Alexa488 (Invitrogen) as the secondary antibody for 1 hr and a monoclonal antibody against the SM-α-actin clone 1A4 (Cy3 conjugate) (Purified Mouse Immunoglobulin) at a dilution of 1:200. After washing in PBS, sections were mounted in Vectashield hard-set mounting medium with DAPI (Vector Laboratories) and viewed under an Axiovert 200M fluorescence microscope. The expression of CaSR was quantified by grey value using the of Image J software. 
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